Literature DB >> 16501924

[Outcome parameters for use in psoriatic arthritis].

J Braun1, S Wassenberg.   

Abstract

The most important and most commonly occurring form of psoriasis is psoriasis vulgaris. In the specialism of rheumatology palmoplantar pustulosis is also important. The outcome is influenced mainly by how severe and how widespread the manifestations affecting the skin and nails are. All manifestations affecting the joints and occurring in association with psoriasis are subsumed under the term 'psoriatic arthritis' (PsA). Asymmetric oligoarthritis, enthesitis and inflammatory spinal manifestations are especially frequent. PsA is a rheumatic illness with widely varying clinical pictures, most patients having signs and symptoms resembling those of spondyloarthritides (SpA) and other features of rheumatoid arthritis (RA) and/or of arthrosis/osteoarthritis (OA). Clinical features that are particularly typical of PsA are ray-wise joint involvement, dactylitis and osteodestructive and osteoproliferative joint destruction. Dactylitis, asymmetric joint involvement and enthesitis also occur in other SpA. It is becoming increasingly important to define outcome parameters for use in PsA against the backdrop of new forms of treatment. In the case of clinical outcome basic distinctions must be made between clinical signs and symptoms, function and structure. In PsA the sometimes significant manifestations affecting skin and nails must also be considered. The outcome parameters used thus far have varied very widely. The extent and intensity of involvement of the peripheral joints and insertions of tendons and of spinal involvement are particularly important in PsA. In addition, functional impairments, quality of life and parameters concerned with work must be considered. There are hardly any measuring instruments specific to PsA; many have been developed and used primarily for SpA or RA.

Entities:  

Mesh:

Year:  2006        PMID: 16501924     DOI: 10.1007/s00393-006-0046-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  81 in total

1.  [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire].

Authors:  J Lautenschläger; W Mau; T Kohlmann; H H Raspe; F Struve; W Brückle; H Zeidler
Journal:  Z Rheumatol       Date:  1997 May-Jun       Impact factor: 1.372

Review 2.  Quantitative joint assessment in rheumatoid arthritis.

Authors:  T Sokka; T Pincus
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

3.  A method to score radiographic change in psoriatic arthritis.

Authors:  S Wassenberg; V Fischer-Kahle; G Herborn; R Rau
Journal:  Z Rheumatol       Date:  2001-06       Impact factor: 1.372

Review 4.  The assessment of disease activity and outcomes in psoriatic arthritis.

Authors:  A Kavanaugh; S Cassell
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

5.  Outcome measures in psoriatic arthritis.

Authors:  Dafna D Gladman; Philip J Mease; Gerald Krueger; Désirée M F M van der Heidje; Christian Antoni; Philip S Helliwell; Arthur F Kavanaugh; Peter Nash; Christopher T Ritchlin; C Vibeke Strand; William Taylor
Journal:  J Rheumatol       Date:  2005-11       Impact factor: 4.666

Review 6.  Psoriatic arthritis imaging: a review of scoring methods.

Authors:  D van der Heijde; J Sharp; S Wassenberg; D D Gladman
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

7.  How to diagnose axial spondyloarthritis early.

Authors:  M Rudwaleit; D van der Heijde; M A Khan; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

8.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

9.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Authors:  J Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F Rosen; Frank Behrens; Peter Jones; Jürgen Wollenhaupt; Franziska G Falk; Philip Mease
Journal:  Arthritis Rheum       Date:  2004-06

10.  Psoriatic spondyloarthropathy in men and women: a clinical, radiographic, and HLA study.

Authors:  D D Gladman; B Brubacher; D Buskila; P Langevitz; V T Farewell
Journal:  Clin Invest Med       Date:  1992-08       Impact factor: 0.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.